MicroRNAs and triple negative breast cancer

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 22202-22220

  D'Ippolito, Elvira ^a   Iorio, Marilena V ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Breast cancer; MicroRNA; Triple negative

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; ESTROGEN RECEPTOR; HERMES ANTIGEN; MICRORNA; MICRORNA 146; MICRORNA 146B-5P; MICRORNA 181A/B; MICRORNA 182; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 203; MICRORNA 205; MICRORNA 21; MICRORNA 31; MICRORNA 34A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; STEM CELL FACTOR; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A;

BIOGENESIS; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER PROGNOSIS; CELL MIGRATION; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; NONHUMAN; ONCOGENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PTEN GENE; RASA1 GENE; REVIEW; TRIPLE NEGATIVE BREAST CANCER; VEGFA GENE;

FEMALE; HUMANS; MICRORNAS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84887444131     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141122202     Document Type: Review

References (155)

1. Kim, V.N.; Nam, J.W. Genomics of microRNA. Trends Genet. 2006, 22, 165-173.
2. Lin, S.L.; Kim, H. Intron-mediated RNA interference and microRNA (miRNA). Front Biosci. 2008, 13, 2216-2230.
3. Lee, Y.; Kim, M. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23, 4051-4060.
4. Yi, R.; Qin, Y. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17, 3011-3016.
5. Hammond, S.M. Dicing and slicing: The core machinery of the RNA interference pathway. FEBS Lett. 2005, 579, 5822-5829.
6. Eulalio, A.; Huntzinger, E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009, 15, 21-32.
7. Qin, W.; Shi, Y. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 2010, 5, e9429.
8. Forman, J.J.; Legesse-Miller, A. A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc. Natl. Acad. Sci. USA 2008, 105, 14879-14884.
9. Place, R.F.; Li, L.C. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl. Acad. Sci. USA 2008, 105, 1608-1613.
10. Li, L.C.; Okino, S.T. Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA 2006, 103, 17337-17342.
11. Hwang, H.W.; Wentzel, E.A. A hexanucleotide element directs microRNA nuclear import. Science 2007, 315, 97-100.
12. Chong, M.M.; Zhang, G. Canonical and alternate functions of the microRNA biogenesis machinery. Genes Dev. 2010, 24, 1951-1960.
13. Cifuentes, D.; Xue, H.A. Novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010, 328, 1694-1698.
14. Cheloufi, S.; Dos Santos, C.O. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010, 465, 584-589.
15. Ruby, J.G.; Jan C.H. Intronic microRNA precursors that bypass Drosha processing. Nature 2007, 448, 83-86.
16. Yang, J.S.; Lai, E.C. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. Mol. Cell 2011, 43, 892-903.
17. Shi, Z.; Zhang, J. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression. Cancer Res. 2013, 73, 5519-5531.
18. Lee, H.C.; Kim, J.G. Prognostic impact of microRNA related gene polymorphisms on survival of patients with colorectal cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 1073-1078.
19. Yang, H.; Dinney, C.P. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008, 68, 2530-2537.
20. Lin, J.; Horikawa, Y. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010, 31, 1805-1812.
21. Liang, D.; Meyer, L. Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. Cancer Res. 2010, 70, 9765-9776.
22. Zhang, X.; Yang, H. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 2010, 31, 2118-2123.
23. Ma, H.; Yuan, H. Genetic variations in key microRNA processing genes and risk of head and neck cancer: A case-control study in Chinese population. PLoS One 2012, 7, e47544.
24. Liu, J.; Liu, J. Genetic variants in the microRNA machinery gene GEMIN4 are associated with risk of prostate cancer: A case-control study of the Chinese Han population. DNA Cell Biol. 2012, 31, 1296-1302.
25. Sung, H.; Jeon S. Common genetic polymorphisms of microRNA biogenesis pathway genes and breast cancer survival. BMC Cancer 2012, 12, doi:10.1186/1471-2407-12-195.
26. Valadi, H.; Ekström, K. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 6, 654-659.
27. Taylor, D.D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110, 13-21.
28. Mitchell, P.S.; Parkin, R.K. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
29. Schwarzenbach, H.; Hoon, D.S. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 2011, 11, 426-437.
30. Hanke, M.; Hoefig, K. A robust methodology to study urine microRNA as tumor marker: MicroRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 2009, 28, 655-661.
31. Park, N.J.; Zhou, H. Salivary microRNA: Discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15, 5473-5477.
32. Michael, A.; Bajracharya, S.D. Exosomes from human saliva as a source of microRNA biomarkers. Oral. Dis. 2010, 16, 34-38.
33. Yu, L.; Todd, N.W. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int. J. Cancer 2010, 127, 2870-2878.
34. Iorio, M.V.; Ferracin, M. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65, 7065-7070.
35. Zhu, S.; Wu, H. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18, 350-359.
36. Yan, L.X.; Huang, X.F. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14, 2348-2360.
37. Qian, B.; Katsaros, D. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res. Treat. 2009, 117, 131-140.
38. Medina, P.P.; Nolde, M. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467, 86-90.
39. Scott, G.K.; Goga, A. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 2006, 12, 1479-1486.
40. Iorio, M.V.; Casalini, P. microRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69, 2195-2200.
41. Yu, F.; Yao, H. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131, 1109-1123.
42. Ma, L.; Teruya-Feldstein, J. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449, 682-688.
43. Ma, L.; Reinhardt, F. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28, 341-347.
44. Ma, L.; Young, J. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010, 12, 247-256.
45. Huang, Q.; Gumireddy, K. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat. Cell Biol. 2008, 10, 202-210.
46. Tavazoie, S.F.; Alarcon, C. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451, 147-152.
47. Gregory, P.A.; Bracken, C.P. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7, 3112-3118.
48. Wu, H.; Zhu, S. Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009, 19, 439-448.
49. Iorio, M.V.; Visone, R. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007, 67, 8699-8707.
50. Perou, C.M.; Sørlie, T. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
51. Teschendorff, A.E.; Miremadi, A. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol. 2007, 8, doi:10.1186/gb-2007-8-8-r157.
52. Prat, A.; Parker, J.S. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010, 12, doi:10.1186/bcr2635.
53. Van de Vijver, M.J.; He, Y.D. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002, 347, 1999-2009.
54. Van't Veer, L.J.; Dai, H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
55. Paik, S.; Shak, S. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351, 2817-2826.
56. Harris, L.; Fritsche, H. American society of clinical oncology. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25, 5287-5312.
57. Nielsen, T.O.; Hsu, F.D. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004, 10, 5367-5374.
58. Blows, F.M.; Driver, K.E. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010, 7, e1000279.
59. Perou, C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16, 61-70.
60. Lehmann, B.D.; Bauer, J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121, 2750-2767.
61. Liedtke, C.; Mazouni C. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26, 1275-1281.
62. Von Minckwitz, G.; Untch, M. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 2012, 30, 1796-1804.
63. Heitz, F.; Harter P. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur. J. Cancer 2009, 45, 2792-2798.
64. Andre, F.; Job, B. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res. 2009, 15, 441-451.
65. Hu, X.; Stern, H.M. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 2009, 7, 511-522.
66. Bertucci, F.; Finetti, P. How basal are triple-negative breast cancers? Int. J. Cancer 2008, 123, 236-240.
67. Gerber, B.; Loibl, S. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers: results from geparquinto study (GBG 44). Annal. Oncol. 2013, doi:10.1093/annonc/mdt361.
68. Bear, H.D.; Tang, G. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 2012, 66, 310-320.
69. Burstein, H.J.; Elias, A.D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26, 1810-1816.
70. Barrios, C.H.; Liu, M.C. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2 negative advanced breast cancer. Breast Cancer Res. Treat. 2010, 121, 121-131.
71. Bergh, J.; Bondarenko, I.M. First-line treatment of advanced breast cancer withsunitinib in combination with docetaxel versus docetaxel alone. J. Clin. Oncol. 2012, 30, 921-929.
72. Baselga, J.; Gómez, P. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J. Clin. Oncol. 2013, 31, 2586-2592.
73. Dickler, M.N.; Rugo, H.S. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 2008, 14, 7878-7883.
74. Blenkiron, C.; Goldstein, L.D. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007, 8, doi:10.1186/gb-2007-8-10-r214.
75. Sempere, L.F.; Christensen, M. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67, 11612-11620.
76. Mattie, M.D.; Benz, C.C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 2006, 5, doi:10.1186/1476-4598-5-24.
77. Lowery, A.J.; Miller, N. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11, doi:10.1186/bcr2257.
78. Janssen, E.A.; Slewa, A. Biologic profiling of lymph node negative breast cancers by means of microRNA expression. Mod. Pathol. 2010, 23, 1567-1576.
79. Farazi, T.A.; Horlings, H.M. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011, 71, 4443-4453.
80. Volinia, S.; Galasso, M. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc. Natl. Acad. Sci. USA 2012, 109, 3024-3029.
81. Dvinge, H.; Git, A. Shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013, 497, 378-382.
82. Li, J.Y.; Jia, S. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes. Asian Pac. J. Cancer Prev. 2013, 14, 3197-3203.
83. Cascione, L.; Gasparini, P. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 2013, 8, e55910.
84. Dedes, K.J.; Natrajan, R. Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. Eur. J. Cancer 2011, 47, 138-150.
85. Passon, N.; Gerometta, A. Expression of Dicer and Drosha in triple-negative breast cancer. J. Clin. Pathol. 2012, 65, 320-326.
86. Piskounova, E.; Polytarchou, C. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 2011, 147, 1066-1079.
87. Martello, G.; Rosato, A. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141, 1195-1207.
88. Buffa, F.M.; Camps, C. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA andmicroRNA expression profiling in breast cancer. Cancer Res. 2011, 71, 5635-5645.
89. Aydoǧdu, E.; Katchy, A. MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis 2012, 33, 1502-1511.
90. Howe, E.N.; Cochrane, D.R. Targets of miR-200c mediate suppression of cell motility and anoikis resistance. Breast Cancer Res. 2011, 13, doi:10.1186/bcr2867.
91. Howe, E.N.; Cochrane, D.R. miR-200c targets a NF-κB up-regulated TrkB/NTF3 autocrine signaling loop to enhance anoikis sensitivity in triplenegative breast cancer. PLoS One 2012, 7, e49987.
92. Piovan, C.; Palmieri, D. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol. Oncol. 2012, 6, 458-472.
93. Wang, C.; Zheng, X. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J. Exp. Clin. Cancer Res. 2012, 31, doi:10.1186/1756-9966-31-58.
94. Sossey-Alaoui, K.; Downs-Kelly, E. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR-31, during the invasion-metastasis cascade. Int. J. Cancer 2011, 129, 1331-1343.
95. Valastyan, S.; Reinhardt, F. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009, 137, 1032-1046.
96. Körner, C.; Keklikoglou, I. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C epsilon (PKCepsilon). J. Biol. Chem. 2013, 288, 8750-8761.
97. Mackiewicz, M.; Huppi, K. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res. Treat. 2011, 130, 663-679.
98. Taylor, M.A.; Sossey-Alaoui, K. TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J. Clin. Invest. 2013, 123, 150-163.
99. Bisso, A.; Faleschini, M. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013, 12, 1679-1687.
100. Garcia, A.I.; Buisson, M. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol. Med. 2011, 3, 279-290.
101. Liu, H.; Wang, Y. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profiling 1. Tumour Biol. 2013, 34, 1713-1722.
102. Wang, J.; Zhao, H. Overexpressions of MicroRNA-9 and MicroRNA-200c in human breast cancers are associated with lymph node metastasis. Cancer Biother. Radiopharm. 2013, 28, 283-288.
103. Castilla, M.Á.; Díaz-Martín, J. MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One 2012, 7, e47709.
104. Blick, T.; Hugo, H. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15, 235-252.
105. Shimono, Y.; Zabala, M. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009, 138, 592-603.
106. Williams, C.; Helguero, L. Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression. Breast Cancer Res. 2009, 11, doi:10.1186/bcr2256.
107. Korpal, M.; Lee, E.S. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283, 14910-14914.
108. Burk, U.; Schubert, J. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9, 582-589.
109. Smit, M.A.; Geiger, T.R. A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis. Mol. Cell Biol. 2009, 29, 3722-3737.
110. Smit, M.A.; Peeper, D.S. Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis. Oncogene 2011, 30, 3735-3744.
111. Chen, J.; Tian, W. Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer. Med. Oncol. 2012, 29, 2527-2534.
112. Lin, J.; Liu, C. miR-200c enhances radiosensitivity of human breast cancer cells. J. Cell Biochem. 2013, 114, 606-615.
113. Radojicic, J.; Zaravinos, A. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle 2011, 10, 507-517.
114. Furuta, M.; Kozaki, K.I. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31, 766-776.
115. Schetter, A.J.; Leung, S.Y. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299, 425-436.
116. Boll, K.; Reiche, K. MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostatecarcinoma. Oncogene 2013, 32, 277-285.
117. Bian, K.; Fan, J. MicroRNA-203 leads to G1 phase cell cycle arrest in laryngeal carcinoma cells by directly targeting survivin. FEBS Lett. 2012, 586, 804-809.
118. Petrarca, C.R.; Brunetto, A.T. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer. Clin. Breast Cancer 2011, 11, 129-134.
119. Kennedy, S.M.; O'Driscoll, L. Prognostic importance of survivin in breast cancer. Br. J. Cancer 2003, 88, 1077-1083.
120. Grunewald, T.G.; Kammerer, U. Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp. Cell Res. 2006, 312, 974-982.
121. Büssing, I.; Slack, F.J. Let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 2008, 14, 400-409.
122. Boyerinas, B.; Park, S.M. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17, F19-F36.
123. Barh, D.; Malhotra, R. MicroRNA let-7: An emerging next-generation cancer therapeutic. Curr. Oncol. 2010, 17, 70-80.
124. Ahmad, A.; Sarkar, S.H. Garcinol regulates EMT and Wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol. Cancer Ther. 2012, 11, 2193-2201.
125. Ahmad, A.; Wang, Z. Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. J. Cell Biochem. 2010, 109, 1134-1141.
126. Kundu, S.T.; Nallur, S. KRAS alleles: The LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle 2012, 11, 361-366.
127. Chin, L.J.; Ratner E. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008, 68, 8535-8540.
128. Paranjape, T.; Heneghan, H. A 3'-untranslated region KRAS variant and triple-negative breast cancer: A case-control and genetic analysis. Lancet Oncol. 2011, 12, 377-386.
129. Lu, L.; Katsaros, D. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with diseaseoutcomes and expression of let-7a and IGF-II. Eur. J. Cancer 2009, 45, 2212-2218.
130. Viswanathan, S.R.; Powers, J.T. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41, 843-848.
131. Wang, Y.C.; Chen, Y.L. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis 2010, 31, 1516-1522.
132. Augoff, K.; McCue, B. miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol. Cancer 2012, 11, doi:10.1186/ 1476-4598-11-5.
133. Shankar, E.; Krishnamurthy, S. PKCepsilon induces Bcl-2 by activating CREB. Int. J. Oncol. 2010, 36, 883-888.
134. Krichevsky, A.M.; Gabriely, G. miR-21: A small multi-faceted RNA. J. Cell Mol. Med. 2009, 13, 9-53.
135. Savad, S.; Mehdipour, P. Expression analysis of MiR-21, MiR-205, and MiR-342 in breast cancer in Iran. Asian Pac. J. Cancer Prev. 2012, 13, 873-877.
136. Kong, W.; He, L. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene 2013, doi:10.1038/onc.2012.636.
137. Chang, S.; Wang, R.H. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat. Med. 2011, 17, 1275-1282.
138. Galluzzi, L.; Morselli, E. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2010, 70, 1793-1803.
139. Guan, P.; Yin, Z. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J. Exp. Clin. Cancer Res. 2012, 31, doi:10.1186/1756-9966-31-54.
140. Liu, Z.; Liu, J. MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J. Pathol. 2012, 228, 204-215.
141. Yanaihara, N.; Caplen, N. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9, 189-198.
142. Li, X.; Zhang, Y. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010, 59, 579-585.
143. Caramuta, S.; Egyházi, S. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest Dermatol. 2010, 130, 2062-2070.
144. Dillhoff, M.; Liu, J. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008, 12, 2171-2176.
145. Rossi, S.; Shimizu, M. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 2010, 116, 945-952.
146. Bader, A.G.; Brown, D. Developing therapeutic microRNAs for cancer. Gene Ther. 2011, 18, 1121-1126.
147. Bader, A.G.; Brown, D. The promise of microRNA replacement therapy. Cancer Res. 2010, 70, 7027-7030.
148. Stenvang, J.; Petri, A. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012, 3, doi:10.1186/1758-907X-3-1.
149. Bader, A.G. miR-34-A microRNA replacement therapy is headed to the clinic. Front Genet. 2012, 3, doi:10.3389/fgene.2012.00120.
150. Trang, P.; Wiggins, J.F. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 2011, 19, 1116-1122.
151. Curtis, C.; Shah, S.P. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486, 346-352.
152. Toyama, T.; Kondo, N. High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn. J. Clin. Oncol. 2012, 42, 256-263.
153. Yamakuchi, M.; Lowenstein, C.J. MiR-34, SIRT1 and p53: The feedback loop. Cell Cycle 2009, 8, 712-715.
154. Svoboda, M.; Sana, J. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012, 7, doi:10.1186/1746-1596-7-31.
155. Baak, J.P.; van Diest, P.J. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J. Clin. Oncol. 2005, 23, 5993-6001.